

# SÃ©bastien Lenglet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4719346/publications.pdf>

Version: 2024-02-01

66  
papers

2,523  
citations

126907

33  
h-index

206112

48  
g-index

66  
all docs

66  
docs citations

66  
times ranked

3763  
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxicity and Metabolomic Impact of Cobalt, Chromium, and Nickel Exposure on HepaRG Hepatocytes. <i>Chemical Research in Toxicology</i> , 2022, 35, 807-816.	3.3	6
2	Vascular-targeted micelles as a specific MRI contrast agent for molecular imaging of fibrin clots and cancer cells. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 158, 347-358.	4.3	9
3	Local Cisplatin Delivery in Mouse Reliably Models Sensorineural Ototoxicity Without Systemic Adverse Effects. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 701783.	3.7	4
4	Renal handling of zinc in chronic kidney disease patients and the role of circulating zinc levels in renal function decline. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1163-1170.	0.7	40
5	Ambulatory Blood Pressure in Relation to Plasma and Urinary Manganese. <i>Hypertension</i> , 2020, 75, 1133-1139.	2.7	8
6	Deficiency of Monoacylglycerol Lipase Enhances IgM Plasma Levels and Limits Atherogenesis in a CB2-Dependent Manner. <i>Thrombosis and Haemostasis</i> , 2019, 119, 348-351.	3.4	9
7	2-Arachidonoylglycerol mobilizes myeloid cells and worsens heart function after acute myocardial infarction. <i>Cardiovascular Research</i> , 2019, 115, 602-613.	3.8	30
8	Alamandine abrogates neutrophil degranulation in atherosclerotic mice. <i>European Journal of Clinical Investigation</i> , 2017, 47, 117-128.	3.4	15
9	Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function. <i>International Journal of Cardiology</i> , 2017, 231, 1-5.	1.7	11
10	Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis. <i>Mediators of Inflammation</i> , 2016, 2016, 1-10.	3.0	17
11	Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 987-997.	3.4	28
12	Treatment with anti-RANKL antibody reduces infarct size and attenuates dysfunction impacting on neutrophil-mediated injury. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 94, 82-94.	1.9	41
13	Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages. <i>Vascular Pharmacology</i> , 2016, 85, 57-65.	2.1	20
14	Gastric bypass in morbid obese patients is associated with reduction in adipose tissue inflammation via N-oleoylethanolamide (OEA)-mediated pathways. <i>Thrombosis and Haemostasis</i> , 2015, 113, 838-850.	3.4	29
15	Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4. <i>Thrombosis and Haemostasis</i> , 2015, 114, 410-422.	3.4	36
16	Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice. <i>Vascular Pharmacology</i> , 2015, 71, 84-92.	2.1	7
17	Treatment with KLEPTOSEÂ® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. <i>Vascular Pharmacology</i> , 2015, 72, 197-208.	2.1	14
18	Role of Matrix Metalloproteinases in Animal Models of Ischemic Stroke. <i>Current Vascular Pharmacology</i> , 2015, 13, 161-166.	1.7	35

#	ARTICLE	IF	CITATIONS
19	Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. <i>Thrombosis and Haemostasis</i> , 2014, 112, 308-322.	3.4	44
20	Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF- $\kappa$ B Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	3.0	26
21	Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse acute pancreatitis. <i>European Journal of Clinical Investigation</i> , 2014, 44, 940-950.	3.4	42
22	Recombinant Tissue Plasminogen Activator Enhances Microglial Cell Recruitment after Stroke in Mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 802-812.	4.3	31
23	Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. <i>Thrombosis and Haemostasis</i> , 2014, 111, 736-747.	3.4	47
24	Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic stroke. <i>Thrombosis and Haemostasis</i> , 2014, 112, 363-378.	3.4	42
25	Inhibition of Nicotinamide Phosphoribosyltransferase Reduces Neutrophil-Mediated Injury in Myocardial Infarction. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 630-641.	5.4	95
26	Role of Matrix Metalloproteinase-8 in Atherosclerosis. <i>Mediators of Inflammation</i> , 2013, 2013, 1-6.	3.0	73
27	Treatment with Evasin-3 Reduces Atherosclerotic Vulnerability for Ischemic Stroke, but Not Brain Injury in Mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 490-498.	4.3	55
28	Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2013, 305, R1323-R1330.	1.8	28
29	Fatty Acid Amide Hydrolase Deficiency Enhances Intraplaque Neutrophil Recruitment in Atherosclerotic Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 215-223.	2.4	52
30	Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. <i>Thrombosis and Haemostasis</i> , 2013, 110, 807-825.	3.4	46
31	Treatment with CB <sub>2</sub> Agonist JWH-133 Reduces Histological Features Associated with Erectile Dysfunction in Hypercholesterolemic Mice. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-11.	3.3	8
32	Alpha-fetoprotein: A controversial prognostic biomarker for small hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 328.	3.3	19
33	Cannabinoid receptor CB2 protects against balloon-induced neointima formation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H1064-H1074.	3.2	23
34	The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. <i>European Heart Journal</i> , 2012, 33, 846-856.	2.2	81
35	CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. <i>European Heart Journal</i> , 2012, 33, 1964-1974.	2.2	107
36	Molecular imaging of matrix metalloproteinases in atherosclerotic plaques. <i>Thrombosis and Haemostasis</i> , 2012, 107, 409-416.	3.4	27

#	ARTICLE	IF	CITATIONS
37	Receptor activator of NF-Î³B ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. <i>Thrombosis and Haemostasis</i> , 2012, 107, 124-139.	3.4	34
38	Toll-Like Receptor 7 Protects From Atherosclerosis by Constraining Inflammatory Macrophage Activation. <i>Circulation</i> , 2012, 126, 952-962.	1.6	92
39	Pathophysiological role of inflammatory molecules in paediatric ischaemic brain injury. <i>European Journal of Clinical Investigation</i> , 2012, 42, 784-794.	3.4	10
40	Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium. <i>Current Signal Transduction Therapy</i> , 2012, 7, 104-110.	0.5	4
41	Matrix metalloproteinase-9: A deleterious link between hepatic ischemia-reperfusion and colorectal cancer. <i>World Journal of Gastroenterology</i> , 2012, 18, 7131.	3.3	5
42	Mass spectrometry for the evaluation of cardiovascular diseases based on proteomics and lipidomics. <i>Thrombosis and Haemostasis</i> , 2011, 106, 20-33.	3.4	39
43	Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. <i>European Heart Journal</i> , 2011, 32, 412-421.	2.2	110
44	Role of CCL-2, CCR-2 and CCR-4 in cerulein-induced acute pancreatitis and pancreatitis-associated lung injury. <i>Journal of Clinical Pathology</i> , 2011, 64, 387-393.	2.0	48
45	Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1519-1525.	1.5	35
46	Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 300, E681-E690.	3.5	17
47	High-Throughput Phospholipidic Fingerprinting by Online Desorption of Dried Spots and Quadrupole-Linear Ion Trap Mass Spectrometry: Evaluation of Atherosclerosis Biomarkers in Mouse Plasma. <i>Analytical Chemistry</i> , 2010, 82, 6687-6694.	6.5	39
48	Single Administration of the CXC Chemokine-Binding Protein Evasin-3 During Ischemia Prevents Myocardial Reperfusion Injury in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1371-1377.	2.4	69
49	Systemic and Intraplaque Mediators of Inflammation Are Increased in Patients Symptomatic for Ischemic Stroke. <i>Stroke</i> , 2010, 41, 1394-1404.	2.0	106
50	Role of the T-Type Calcium Channel Ca <sub>v</sub> 3.2 in the Chronotropic Action of Corticosteroids in Isolated Rat Ventricular Myocytes. <i>Endocrinology</i> , 2009, 150, 3726-3734.	2.8	35
51	CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. <i>Journal of Molecular and Cellular Cardiology</i> , 2009, 46, 612-620.	1.9	153
52	Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. <i>Atherosclerosis</i> , 2009, 205, 433-441.	0.8	67
53	Corticosteroids and Redox Potential Modulate Spontaneous Contractions in Isolated Rat Ventricular Cardiomyocytes. <i>Hypertension</i> , 2008, 52, 721-728.	2.7	57
54	Hint2 Is Expressed in the Mitochondria of H295R Cells and Is Involved in Steroidogenesis. <i>Endocrinology</i> , 2008, 149, 5461-5469.	2.8	16

#	ARTICLE	IF	CITATIONS
55	Molecular Design Based on 3D Pharmacophores. Applications to 5-HT7 Receptors.. ChemInform, 2004, 35, no.	0.0	0
56	Molecular Design Based on 3D Pharmacophores. Applications to 5-HT7Receptors. Journal of Chemical Information and Computer Sciences, 2004, 44, 1148-1152.	2.8	18
57	INVOLVEMENT OF T-TYPE CALCIUM CHANNELS IN THE MECHANISM OF ACTION OF 5-HT IN RAT GLOMERULOSA CELLS: A NOVEL SIGNALING PATHWAY FOR THE 5-HT7 RECEPTOR. Endocrine Research, 2002, 28, 651-655.	1.2	13
58	Activation of 5-HT7 Receptor in Rat Glomerulosa Cells Is Associated with an Increase in Adenylyl Cyclase Activity and Calcium Influx through T-Type Calcium Channels. Endocrinology, 2002, 143, 1748-1760.	2.8	65
59	Activation of 5-HT7 Receptor in Rat Glomerulosa Cells Is Associated with an Increase in Adenylyl Cyclase Activity and Calcium Influx through T-Type Calcium Channels. Endocrinology, 2002, 143, 1748-1760.	2.8	20
60	Role of neurotransmitters and neuropeptides in the regulation of the adrenal cortex. Reviews in Endocrine and Metabolic Disorders, 2001, 2, 253-267.	5.7	36
61	Role of 5-HT in the regulation of the brain-pituitary-adrenal axis: effects of 5-HT on adrenocortical cells. Canadian Journal of Physiology and Pharmacology, 2000, 78, 967-983.	1.4	63
62	Role of 5-HT in the regulation of the brain-pituitary-adrenal axis: effects of 5-HT on adrenocortical cells. Canadian Journal of Physiology and Pharmacology, 2000, 78, 967-983.	1.4	30
63	Pharmacological and Molecular Characterization of 5-Hydroxytryptamine <sub>7</sub> Receptors in the Rat Adrenal Gland. Molecular Pharmacology, 1999, 56, 552-561.	2.3	40
64	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene, 1998, 16, 1369-1372.	5.9	75
65	Pharmacological and Functional Characterization of Muscarinic Receptors in the Frog Pars Intermedia1. Endocrinology, 1998, 139, 3525-3533.	2.8	15
66	Pharmacological and Functional Characterization of Muscarinic Receptors in the Frog Pars Intermedia. Endocrinology, 1998, 139, 3525-3533.	2.8	7